Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DZD8586 + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone
- Development stage
- Phase 3
- Lead developer
- Dizal Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This drug is a **combination regimen** comprising DZD8586 (an investigational agent), rituximab (a monoclonal antibody targeting CD20 on B cells), cyclophosphamide (an alkylating agent), doxorubicin (an anthracycline antibiotic), vincristine (a vinca alkaloid), and prednisone (a synthetic glucocorticoid corticosteroid). It is an experimental combination under clinical development, likely for the treatment of lymphoid malignancies such as diffuse large B-cell lymphoma. - **DZD8586**: Mechanism and profile are investigational; limited public data. - **Rituximab**: Depletes B cells via anti-CD20 activity[3]. - **Cyclophosphamide**: DNA cross-linking; cytotoxic to proliferating cells. - **Doxorubicin**: Intercalates into DNA; inhibits topoisomerase II. - **Vincristine**: Inhibits microtubule formation; arrests mitosis. - **Prednisone**: Anti-inflammatory, immunosuppressive glucocorticoid. This combination is a variant of the established R-CHOP protocol, often used for treating aggressive B-cell lymphomas[1][3][5].
- Other names
- DZD8586 + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone
02
Targets
BTK (Bruton tyrosine kinase)CD20 (B-lymphocyte antigen CD20)DNALYN (LYN proto-oncogene, Src family tyrosine kinase)GR (Glucocorticoid receptor)TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on DZD8586 + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DZD8586 + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone.